Senseonics Holdings, Inc. (NYSE: SENS), the developer of the Eversense 365 Continuous Glucose Monitoring (CGM) System, witnessed a significant surge in its stock price, soaring nearly 7% in pre-market trading on Wednesday.
The pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patients using Eversense 365, the world's first and only One Year CGM system.
The integration is expected to enhance patient care by enabling timely treatment adjustments based on regular CGM data reviews, ultimately improving glycemic control and patient outcomes. Additionally, it unlocks new revenue opportunities for healthcare providers through automated capture of reimbursable care events, making the partnership both clinically impactful and operationally efficient.